We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+16.68%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+632.23%
AUM
$88.8B
AUM Growth
+$10B
(+13%)
Cap. Flow
+$220M
Cap. Flow
% of AUM
0.25%
Top 10 Holdings %
Top 10 Hldgs %
31.47%
Holding
3,325
New
753
Increased
947
Reduced
893
Closed
691
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRCL
Circle Internet Group
CRCL
|
+$1.39B |
| 2 |
NVIDIA
NVDA
|
+$910M |
| 3 |
Amazon
AMZN
|
+$440M |
| 4 |
T-Mobile US
TMUS
|
+$432M |
| 5 |
Eli Lilly
LLY
|
+$398M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$1.3B |
| 2 |
Tesla
TSLA
|
+$880M |
| 3 |
Danaher
DHR
|
+$535M |
| 4 |
Intuit
INTU
|
+$467M |
| 5 |
Visa
V
|
+$437M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.88% |
| 2 | Consumer Discretionary | 13.54% |
| 3 | Healthcare | 10.42% |
| 4 | Financials | 8.78% |
| 5 | Communication Services | 7.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2526
Relmada Therapeutics
RLMD
$484M
| $92.7K | ﹤0.01% |
+154,568
| New | +$79.3K |
|
2527
Genelux
GNLX
$122M
| $92.5K | ﹤0.01% |
+32,221
| New | +$85.1K |
|
2528
PDS Biotechnology
PDSB
$40.9M
| $91K | ﹤0.01% |
+68,454
| New | +$93K |
|
2529
Tenaya Therapeutics
TNYA
$165M
| $90.3K | ﹤0.01% |
+148,089
| New | +$75.4K |
|
|
LNAI
2530
Lunai Bioworks
LNAI
$10.7M
| $89.7K | ﹤0.01% |
+3,867
| New | +$108K |
|
2531
Atea Pharmaceuticals
AVIR
$402M
| $89.5K | ﹤0.01% |
+24,867
| New | +$74.2K |
|
|
MVO
2532
DELISTED
MV Oil Trust
MVO
| $88K | ﹤0.01% |
+15,270
| New | +$88.6K |
|
2533
FerroAtlántica
GSM
$865M
| $87.7K | ﹤0.01% |
23,900
-791,613
| -97% | -$2.91M |
|
|
FOLD
2534
DELISTED
Amicus Therapeutics
FOLD
| $86.3K | ﹤0.01% |
15,062
-181,051
| -92% | -$1.17M |
|
2535
UNIFI
UFI
$129M
| $86.1K | ﹤0.01% |
16,492
-86,745
| -84% | -$427K |
|
2536
Altimmune
ALT
$593M
| $85.5K | ﹤0.01% |
22,100
-1,146,238
| -98% | -$6.2M |
|
2537
LanzaTech
LNZA
$70.1M
| $82.2K | ﹤0.01% |
+3,045
| New | +$74.7K |
|
2538
PUT
Vanguard Real Estate ETF
VNQ
$38.6B
| $80.2K | ﹤0.01% |
+900
| New | +$79.4K |
|
|
HURA
2539
TuHURA Biosciences
HURA
$137M
| $79.3K | ﹤0.01% |
+35,571
| New | +$120K |
|
|
ARTV
2540
Artiva Biotherapeutics
ARTV
$549M
| $78.8K | ﹤0.01% |
+52,213
| New | +$110K |
|
2541
Century Therapeutics
IPSC
$357M
| $78.2K | ﹤0.01% |
+139,707
| New | +$75K |
|
2542
TScan Therapeutics
TCRX
$50.1M
| $77.8K | ﹤0.01% |
+53,678
| New | +$77.5K |
|
2543
Green Plains
GPRE
$1.06B
| $77K | ﹤0.01% |
12,771
-386,724
| -97% | -$1.7M |
|
2544
CervoMed
CRVO
$26.5M
| $75.6K | ﹤0.01% |
+12,017
| New | +$102K |
|
2545
Annexon
ANNX
$883M
| $72K | ﹤0.01% |
+29,989
| New | +$60.1K |
|
2546
Smart Sand
SND
$197M
| $71.9K | ﹤0.01% |
35,749
-31,953
| -47% | -$64.7K |
|
|
AUNA
2547
Auna
AUNA
$390M
| $70.9K | ﹤0.01% |
11,428
-10,553
| -48% | -$70.9K |
|
2548
Tilly's
TLYS
$130M
| $69.7K | ﹤0.01% |
+50,500
| New | +$69.4K |
|
2549
VistaGen Therapeutics
VTGN
$11.7M
| $69.3K | ﹤0.01% |
+34,638
| New | +$78.7K |
|
|
MRSN
2550
DELISTED
Mersana Therapeutics
MRSN
| $68.1K | ﹤0.01% |
+9,079
| New | +$79.8K |
|
Similar funds
Marshall Wace's Q2 2025 Portfolio in Review
As of Q2 2025, Marshall Wace held 3,325 positions worth $88.8B, up 13% from $78.8B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Marshall Wace's Q2 2025 filing shows 753 new, 947 increased, 893 reduced and 691 closed positions. Its largest new stake was Circle Internet Group: 8,534,470 shares worth $1.55B. The largest sale was iShares Core S&P 500 ETF, an estimated $1.3B.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 18% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- Marshall Wace's largest Q2 2025 buy was Circle Internet Group: 8,534,470 shares worth $1.55B.
- Marshall Wace added most to NVIDIA in Q2 2025, an estimated $910M increase.
- Marshall Wace's biggest Q2 2025 reduction was iShares Core S&P 500 ETF, cutting an estimated $1.3B.
- Marshall Wace fully exited Cboe Global Markets in Q2 2025, selling an estimated $191M.
- Marshall Wace's ten largest holdings make up 31% of its $88.8B portfolio in Q2 2025.
- Marshall Wace opened 753 new positions and closed 691 in Q2 2025.
- Marshall Wace's portfolio value rose 13% quarter-over-quarter to $88.8B.
Based on Marshall Wace's 13F filing for Q2 2025, filed 13 Aug 2025.